SCHEMBL23215775

SCHEMBL23215775

O=C(O)Cc1ccc(Br)c(F)c1.O=C(O)c1ccc(Br)c(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 2/20 0.46
KDM4E B2RXH2 3/20 0.42
MAPT P10636 3/20 0.42
HPGD P15428 3/20 0.42
HSD17B10 Q99714 3/20 0.42
LMNA P02545 2/20 0.42
RGS12 O14924 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
APEX1 P27695 1/20 0.42
THPO P40225 1/20 0.42
BLM P54132 1/20 0.42
GNAI1 P63096 1/20 0.42
PMP22 Q01453 1/20 0.42
HIF1A Q16665 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511925 0.90 KDM4E (0.50) SRD5A2KDM4EMAPTHPGDHSD17B10
SCHEMBL29393171 0.90 KDM4E (0.50) SRD5A2KDM4EMAPTHPGDHSD17B10
Methane SCHEMBL28535162 0.89 KDM4E (0.48) SRD5A2KDM4EMAPTHPGDHSD17B10
SCHEMBL7694625 0.86 RARB (0.44) MAPTHPGDHSD17B10LMNATSHR
SCHEMBL286942 0.85 HTT (0.53) SRD5A2KDM4EMAPTHPGDHSD17B10
SCHEMBL30523532 0.85 HTT (0.53) SRD5A2KDM4EMAPTHPGDHSD17B10
SCHEMBL77380 0.76 KDM4E (0.50) SRD5A2KDM4EMAPTHPGDHSD17B10
SCHEMBL23215776 0.76 PTPRB (0.37) SRD5A2GAAPTGDR2PTPRBKMT2A
SCHEMBL7559862 0.76 HTT (0.49) SRD5A2KDM4EMAPTHPGDLMNA
SCHEMBL20512834 0.75 CA2 (0.47) KDM4EHPGDLMNAPOLBNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 US disclosed
US-20220153719-A1 GPR119 AGONISTS KALLYOPE, INC. 2022-05-19 US disclosed
WO-2021071837-A1 GPR119 AGONISTS KALLYOPE, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230061736-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR SRD5A2 1379/4885KDM4E 1450/4885MAPT 2329/4885
US-20220153719-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR SRD5A2 1379/4885KDM4E 1450/4885MAPT 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.